# 99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer

> **NCT04233476** · PHASE3 · COMPLETED · sponsor: **RDO Pharm.** · enrollment: 409 (actual)

## Conditions studied

- Lung Cancer
- Lymph Node Metastasis

## Interventions

- **DRUG:** 99mTc-3PRGD2 injection

## Key facts

- **NCT ID:** NCT04233476
- **Lead sponsor:** RDO Pharm.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-12
- **Primary completion:** 2021-05-08
- **Final completion:** 2021-05-08
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2024-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233476, "99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04233476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*